MX375355B - Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral. - Google Patents
Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.Info
- Publication number
- MX375355B MX375355B MX2016009665A MX2016009665A MX375355B MX 375355 B MX375355 B MX 375355B MX 2016009665 A MX2016009665 A MX 2016009665A MX 2016009665 A MX2016009665 A MX 2016009665A MX 375355 B MX375355 B MX 375355B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- intracerebral hemorrhage
- treating
- treating intracerebral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931071P | 2014-01-24 | 2014-01-24 | |
| PCT/IB2015/050313 WO2015110939A1 (en) | 2014-01-24 | 2015-01-15 | Compositions and methods for treating intracerebral hemorrhage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016009665A MX2016009665A (es) | 2016-11-14 |
| MX375355B true MX375355B (es) | 2025-03-04 |
Family
ID=52630418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009665A MX375355B (es) | 2014-01-24 | 2015-01-15 | Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20160375109A1 (enExample) |
| EP (1) | EP3096779B1 (enExample) |
| JP (1) | JP6624787B2 (enExample) |
| KR (3) | KR20160093731A (enExample) |
| CN (2) | CN105934250A (enExample) |
| AU (1) | AU2015208819B2 (enExample) |
| BR (1) | BR112016014617A2 (enExample) |
| CA (1) | CA2937418A1 (enExample) |
| DK (1) | DK3096779T3 (enExample) |
| ES (1) | ES2772802T3 (enExample) |
| HU (1) | HUE047588T4 (enExample) |
| IL (1) | IL246637A0 (enExample) |
| MX (1) | MX375355B (enExample) |
| PL (1) | PL3096779T3 (enExample) |
| PT (1) | PT3096779T (enExample) |
| RU (1) | RU2016126423A (enExample) |
| SI (1) | SI3096779T1 (enExample) |
| WO (1) | WO2015110939A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1215196A1 (zh) | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
| CN112195169A (zh) | 2013-09-24 | 2021-01-08 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
| KR20260076240A (ko) | 2024-11-18 | 2026-05-28 | 한림대학교 산학협력단 | 뇌내출혈 질환 진단용 rs5117 마커 조성물 및 이의 용도 |
| KR20260076239A (ko) | 2024-11-18 | 2026-05-28 | 한림대학교 산학협력단 | 뇌내출혈 질환 진단용 rs429358 마커 조성물 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06015045A (es) * | 2004-06-21 | 2007-03-21 | Novo Nordisk Healthcare Ag | Uso del factor viia o equivalentes del factor viia para prevenir o atenuar el crecimiento de hemorragias y/o generacion de edemas despues de una hemorragia intracerebral. |
| MX336958B (es) | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| JP2011509978A (ja) * | 2008-01-18 | 2011-03-31 | ノボ ノルディスク ヘルス ケア アーゲー | 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用 |
| EP2453910B1 (en) * | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
| EP2467166A2 (en) * | 2009-08-20 | 2012-06-27 | CSL Behring GmbH | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| JP6514893B2 (ja) * | 2011-09-30 | 2019-05-15 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 止血を調節するための組成物および方法 |
| KR102049900B1 (ko) * | 2012-07-25 | 2019-11-28 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 변형 인자 x 폴리펩티드 및 이의 용도 |
| HK1215196A1 (zh) * | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
-
2015
- 2015-01-15 CN CN201580005696.XA patent/CN105934250A/zh active Pending
- 2015-01-15 CA CA2937418A patent/CA2937418A1/en not_active Abandoned
- 2015-01-15 WO PCT/IB2015/050313 patent/WO2015110939A1/en not_active Ceased
- 2015-01-15 US US15/112,088 patent/US20160375109A1/en not_active Abandoned
- 2015-01-15 EP EP15708578.8A patent/EP3096779B1/en not_active Not-in-force
- 2015-01-15 AU AU2015208819A patent/AU2015208819B2/en not_active Ceased
- 2015-01-15 KR KR1020167019778A patent/KR20160093731A/ko not_active Ceased
- 2015-01-15 RU RU2016126423A patent/RU2016126423A/ru not_active Application Discontinuation
- 2015-01-15 SI SI201531081T patent/SI3096779T1/sl unknown
- 2015-01-15 DK DK15708578.8T patent/DK3096779T3/da active
- 2015-01-15 MX MX2016009665A patent/MX375355B/es active IP Right Grant
- 2015-01-15 PT PT157085788T patent/PT3096779T/pt unknown
- 2015-01-15 ES ES15708578T patent/ES2772802T3/es active Active
- 2015-01-15 KR KR1020217001254A patent/KR20210008177A/ko not_active Ceased
- 2015-01-15 KR KR1020187002632A patent/KR20180014221A/ko not_active Ceased
- 2015-01-15 CN CN202011260045.4A patent/CN112156176A/zh active Pending
- 2015-01-15 PL PL15708578T patent/PL3096779T3/pl unknown
- 2015-01-15 BR BR112016014617A patent/BR112016014617A2/pt not_active IP Right Cessation
- 2015-01-15 HU HUE15708578A patent/HUE047588T4/hu unknown
- 2015-01-23 JP JP2015011332A patent/JP6624787B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-06 IL IL246637A patent/IL246637A0/en unknown
-
2018
- 2018-10-11 US US16/157,194 patent/US20190231856A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3096779T3 (da) | 2020-02-24 |
| BR112016014617A2 (pt) | 2017-09-19 |
| JP6624787B2 (ja) | 2019-12-25 |
| SI3096779T1 (sl) | 2020-03-31 |
| CN105934250A (zh) | 2016-09-07 |
| HUE047588T2 (hu) | 2020-04-28 |
| AU2015208819A1 (en) | 2016-06-30 |
| PT3096779T (pt) | 2020-02-21 |
| WO2015110939A1 (en) | 2015-07-30 |
| EP3096779B1 (en) | 2019-12-18 |
| US20160375109A1 (en) | 2016-12-29 |
| HUE047588T4 (hu) | 2020-06-29 |
| JP2015147764A (ja) | 2015-08-20 |
| US20190231856A1 (en) | 2019-08-01 |
| KR20210008177A (ko) | 2021-01-20 |
| PL3096779T3 (pl) | 2020-05-18 |
| IL246637A0 (en) | 2016-08-31 |
| RU2016126423A3 (enExample) | 2018-03-01 |
| EP3096779A1 (en) | 2016-11-30 |
| ES2772802T3 (es) | 2020-07-08 |
| KR20180014221A (ko) | 2018-02-07 |
| CN112156176A (zh) | 2021-01-01 |
| KR20160093731A (ko) | 2016-08-08 |
| MX2016009665A (es) | 2016-11-14 |
| CA2937418A1 (en) | 2015-07-30 |
| RU2016126423A (ru) | 2018-03-01 |
| AU2015208819B2 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| IL251759A0 (en) | Preparations and methods for treating insomnia | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| BR112017009000A2 (pt) | apilimod para uso no tratamento de melanoma | |
| PH12017501022A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| GB2542080B (en) | Non-reducing stabilization complexant for acidizing compositions and associated methods | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| JO3628B1 (ar) | كينازولين مهلجن-thf-أمينات على هيئة مثبطات pde1 | |
| IL253220A0 (en) | Preparations and methods for the treatment of glaucoma | |
| PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
| IL246637A0 (en) | Preparations and methods for the treatment of intracerebral hemorrhage | |
| MY167350A (en) | Fat-and-oil composition and chocolate | |
| NZ711523A (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| IL249152B (en) | Botulinum toxin for use in the treatment of paratonia | |
| PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
| SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |